Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Transitional Cell
Neoplasm Recurrence, Local
Urinary Bladder Neoplasms
The combination of gemcitabine and taxol in previously treated patients with recurrent TCC is highly effective and produces objective durable responses. This every-2-week schedule is a well tolerated outpatient regimen with minimal toxicity.